Preclinical
MOTS-c
MOTS-c is a 16-residue peptide encoded by a short open reading frame in mitochondrial 12S rRNA. It was described as a mitochondrial-derived peptide with metabolic effects in animals.
Research summary only. Not medical advice, not a protocol, and not for human or veterinary consumption.
- Also called
- Mitochondrial ORF of the 12S rRNA type-c
- Sequence or structure
- MRWQEMGYIFYPRKLR
- Evidence
- Preclinical
Mechanism
The founding papers describe it as a regulator of metabolic homeostasis, with actions that include AMPK-related signalling in preclinical models. A mitochondrial gene product studied in mice is not a human metabolic therapy.
Evidence
Lee, Kim, and colleagues reported MOTS-c in Cell Metabolism in 2015. Subsequent work is still largely preclinical, with early human observational interest and no approval.
Limitations
Sequence variants and synthetic modifications would be a different substance. Not for human use.
